FDA approves Ibrance for postmenopausal women with metastatic breast cancer
On February 3, the U.S. Food and Drug Administration (FDA) approved Ibrance (palbociclib) to treat advanced metastatic breast cancer. Read more.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.